These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
United Therapeutics Corporation (UTHR) Q4 2024 Earnings Call Transcript
Start Time: 09:00 January 1, 0000 9:31 AM ET United Therapeutics Corporation (NASDAQ:UTHR ) Q4 2024 Earnings Conference Call February 26, 2025, 09:00 AM ET Company Participants Martine Rothblatt - Chairperson and CEO Michael Benkowitz - President and COO James Edgemond - CFO and Treasurer Leigh Peterson - EVP, Product Development and Xenotransplantation Pat Poisson - EVP, Technical Operations Dewey Steadman - Head, IR Conference Call Participants Roger Song - Jefferies Jessica Fye - JPMorgan Ash Verma - UBS Joseph Thome - TD Cowen Roanna Ruiz - Leerink Andreas Argyrides - Oppenheimer Operator Good morning, and welcome to the United Therapeutics Corporation Fourth Quarter 2024 Corporate Update. My name is Cindy, and I will be your conference operator today.
United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat
UTHR beats fourth-quarter estimates for both earnings and sales. Tyvaso sales fall short of estimates.
United Therapeutics (UTHR) Surpasses Q4 Earnings and Revenue Estimates
United Therapeutics (UTHR) came out with quarterly earnings of $6.19 per share, beating the Zacks Consensus Estimate of $6.10 per share. This compares to earnings of $4.36 per share a year ago.
United Therapeutics: A Unique Business With High Margins And Expansion Potential
United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by Tyvaso (+33% YoY), and maintains high margins and low debt burden, with a 39% growth potential. Key growth drivers include Tyvaso's expansion into IPF, Ralinepag development, xenotransplantation breakthroughs, and international market expansion.
Seeking Clues to United Therapeutics (UTHR) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for United Therapeutics (UTHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Strength Seen in United Therapeutics (UTHR): Can Its 4.9% Jump Turn into More Strength?
United Therapeutics (UTHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
UTHR or ZTS: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are Medical Stocks Lagging United Therapeutics (UTHR) This Year?
Here is how United Therapeutics (UTHR) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
